Endocrine Oncology

Submit your manuscript Author guidelines Journal scope Open access Publication charges Editorial Board

EDITOR-IN-CHIEF

Edward P Gelmann, MD
John Norton Professor of Prostate Cancer Research,
Arizona Cancer Centre, University of Arizona,
AZ, USA

Browse the full Editorial Board

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?

Author: Sunita M C De Sousa

Low but not undetectable early postoperative nadir serum cortisol predicts sustained remission in Cushing’s disease

Authors: Anna Stroud, Pearl Dhaliwal, Richard J Harvey, Raquel Alvarado, Benjamin P Jonker, Mark J Winder, Jessica W Grayson, and Ann McCormack

Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center

Authors: Sara Coelho, Cláudia Costa, Ana Paula Santos, Pedro Souteiro, Joana Oliveira, Júlio Oliveira, Isabel Azevedo, Isabel Torres, and Maria José Bento

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogues and decitabine

Authors: Syed Ehsanullah and Nikolaos A Trikalinos

Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations

Authors: Erika Peverelli, Donatella Treppiedi, and Giovanna Mantovani

January 26, 2021

Article Publication Charge Waived

In celebration of the launch of Endocrine Oncology, Bioscientifica is sponsoring the Article Publication Charge during the launch years of the journal.

January 26, 2021

Endocrine Oncology – now open for submissions

Bioscientifica is pleased to announce the launch of their new fully open-access, peer-reviewed journal, Endocrine Oncology, endorsed by the Society for Endocrinology.

Led by Editor-in-Chief Edward P Gelmann, Endocrine Oncology will see vigorous yet rapid peer review of the latest basic, translational and clinical research in the field.

RSS Feed

More News

Tweets by EndoOncology